Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of Adavosertib in Advanced Solid Tumours
NCT05008913Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in solid tumor (advanced stage), sponsored by AstraZeneca. Primary endpoints: Amount and cumulative amount excreted and expressed as the percentage of the administered dose into the urine and faeces, Renal clearance of radioactivity (CLR) and 5 more. Started Oct 2021; status: terminated.
02
Drugs
adavosertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05008913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008913.